Table 2.

Risk of HR-negative or -positive breast cancer associated with statin use

Statin useHR-negative cases, n = 3,996 (col%)Matched controls, n = 39,960 (col%)*OR (95% CI)HR-positive cases, n = 18,492 (col%)Matched controls, n = 184,900 (col%)OR (95% CI)§
Never3,160 (79.1)31,694 (79.3)Reference13,919 (75.3)138,122 (74.7)Reference
≥2 y260 (6.5)2,612 (6.5)0.98 (0.84-1.13)1,628 (8.8)16,002 (8.7)1.03 (0.97-1.10)
Never3,160 (79.1)31,694 (79.3)Reference13,919 (75.3)138,122 (74.7)Reference
<1 y440 (11.0)4,477 (11.2)1.02 (0.91-1.16)2,299 (12.4)24,107 (13.0)1.00 (0.95-1.05)
≥1-2 y136 (3.4)1,177 (2.9)1.17 (0.97-1.41)646 (3.5)6,669 (3.6)0.97 (0.89-1.05)
≥2-3 y93 (2.3)831 (2.1)1.13 (0.91-1.42)475 (2.6)4,827 (2.6)0.98 (0.89-1.08)
≥3-5 y96 (2.4)1,040 (2.6)0.93 (0.75-1.16)604 (3.3)6,099 (3.3)0.99 (0.90-1.08)
≥5 y71 (1.8)741 (1.9)0.97 (0.75-1.25)549 (3.0)5,076 (2.7)1.08 (0.98-1.19)

Abbreviation: OR, odds ratio

  • *Controls matched to HR-negative cases bases on age at diagnosis/index date and years of coverage.

  • Odds ratios based on conditional logistic regression among HR-negative cases and their matched controls, adjusted for oral contraceptive and hormone therapy use.

  • Controls matched to HR-positive cases bases on age at diagnosis/index date and years of coverage.

  • §Odds ratios based on conditional logistic regression among HR-positive cases and their matched controls, adjusted for oral contraceptive and hormone therapy use.